Optimum Induction Therapy of Low-risk Acute Promyelocytic Leukemia With All Oral Drugs
Despite the high cure probability for acute promyelocytic leukemia (APL), a minority of patients will relapse and the risk factors for relapse are unclear. The goal of this clinical trial is to compare the effectiveness and safety of induction of oral all-trans retinoic acid (ATRA) and realgar-indigo naturalis formula (RIF) combined with oral etoposide or daunorubicin as cytoreductive therapies in low-risk APL. The present study was to explored a cytoreduction of an oral etoposide for low-risk APL with dual induction of ATRA and RIF as a high efficacy, low recurrence, and more convenient all-oral regimen.
• Newly diagnosed APL patients (WHO 2008 diagnostic classification);
• 18-75 years old;
• Liver function: propionate hydrogentransferase (ALT) and aspartate hydrogentransferase (AST) ≤ 2.5 times the upper limit of normal value, bilirubin ≤ 2 times the upper limit of normal value;
• Renal function: muscle salt ≤ 3 times the upper limit of normal value;
• The physical strength score is 0-2 (ECOG);
• White blood cells ≤ 10×109/L;
• Subjects must sign an informed consent form.